Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTSNASDAQ:EXOZNASDAQ:MGNXNASDAQ:PULM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTSJanone$5.51+0.7%$4.99$1.29▼$7.75$88.60M2.08228,549 shs117,808 shsEXOZExozymes$13.53+14.8%$13.35$8.50▼$23.99$113.22MN/A19,658 shs15,616 shsMGNXMacroGenics$1.71+12.5%$1.86$0.99▼$16.48$107.88M2.231.14 million shs1.05 million shsPULMPulmatrix$6.47+2.5%$7.03$1.72▼$10.40$23.62M1.55132,554 shs8,775 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTSJanone-1.62%+45.09%+15.64%+13.02%+546,999,900.00%EXOZExozymes+12.61%+0.34%-20.39%+1,178,999,900.00%+1,178,999,900.00%MGNXMacroGenics+9.35%+20.63%-24.00%-50.65%-90.14%PULMPulmatrix+2.44%+16.85%-15.53%+3.27%+213.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTSJanoneN/AN/AN/AN/AN/AN/AN/AN/AEXOZExozymesN/AN/AN/AN/AN/AN/AN/AN/AMGNXMacroGenics3.5824 of 5 stars3.21.00.04.42.12.50.6PULMPulmatrixN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTSJanone 0.00N/AN/AN/AEXOZExozymes 0.00N/AN/AN/AMGNXMacroGenics 2.36Hold$7.38331.29% UpsidePULMPulmatrix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PULM, ALTS, MGNX, and EXOZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2025MGNXMacroGenicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.00 ➝ $2.00(Data available from 4/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTSJanone$12.53M7.07N/AN/A($0.67) per share-8.22EXOZExozymesN/AN/AN/AN/AN/AN/AMGNXMacroGenics$148.34M0.73N/AN/A$2.46 per share0.70PULMPulmatrix$7.81M3.03N/AN/A$4.93 per share1.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTSJanone-$7.81MN/A0.00∞N/AN/A-2,940.01%-39.81%N/AEXOZExozymesN/AN/A0.00∞N/AN/AN/AN/AN/AMGNXMacroGenics-$9.06M-$1.08N/AN/AN/A-69.07%-89.42%-38.57%5/8/2025 (Estimated)PULMPulmatrix-$14.12M-$2.61N/A∞N/A-96.51%-45.97%-30.72%5/9/2025 (Estimated)Latest PULM, ALTS, MGNX, and EXOZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025MGNXMacroGenics-$0.61N/AN/AN/A$9.59 millionN/A3/21/2025Q4 2024PULMPulmatrixN/A-$0.54N/A-$0.54N/AN/A3/20/2025Q4 2024MGNXMacroGenics-$0.23-$0.25-$0.02-$0.25$34.17 million$49.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTSJanone$1.2222.14%N/AN/AN/AEXOZExozymesN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTSJanone1.960.750.75EXOZExozymesN/AN/AN/AMGNXMacroGenicsN/A3.753.69PULMPulmatrixN/A19.4019.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTSJanone6.27%EXOZExozymesN/AMGNXMacroGenics96.89%PULMPulmatrix11.84%Insider OwnershipCompanyInsider OwnershipALTSJanone4.90%EXOZExozymesN/AMGNXMacroGenics11.30%PULMPulmatrix0.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTSJanone17016.08 million13.38 millionN/AEXOZExozymes298.37 millionN/AN/AMGNXMacroGenics43063.09 million55.67 millionOptionablePULMPulmatrix203.65 million3.63 millionNot OptionablePULM, ALTS, MGNX, and EXOZ HeadlinesRecent News About These CompaniesAspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, PulmocideApril 3, 2025 | theglobeandmail.comPulmatrix Reports 2024 Financials and Merger PlansMarch 25, 2025 | tipranks.comPulmatrix Inc.: Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for AssetsMarch 21, 2025 | finanznachrichten.dePulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for AssetsMarch 21, 2025 | prnewswire.comPulmatrix revises bylaws, changes voting standardsFebruary 14, 2025 | msn.comCullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic PainJanuary 23, 2025 | finance.yahoo.comHow to Take Advantage of moves in (PULM)January 11, 2025 | news.stocktradersdaily.comWhen the Price of (PULM) Talks, People ListenDecember 11, 2024 | news.stocktradersdaily.comPulmatrix Inc (PULM) Stock: Surpassing Expectations in the MarketNovember 19, 2024 | bovnews.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of ShareholdersNovember 15, 2024 | accesswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULMNovember 15, 2024 | bakersfield.comPULM INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Pulmatrix, Inc. MergerNovember 14, 2024 | accesswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULMNovember 14, 2024 | globenewswire.comPulmatrix Inc.: Pulmatrix and Cullgen Announce Proposed MergerNovember 14, 2024 | finanznachrichten.dePULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to ShareholdersNovember 14, 2024 | joplinglobe.comFramingham-based biopharma company announces merger agreement with San Diego firmNovember 14, 2024 | wbjournal.comPulmatrix Shares Surge on Merger with CullgenNovember 14, 2024 | marketwatch.comPulmatrix Shares Hit 52-Week High After News of Merger DealNovember 14, 2024 | marketwatch.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of ShareholdersNovember 14, 2024 | globenewswire.comShareholder Alert: Ademi LLP investigates whether Pulmatrix, Inc. is obtaining a Fair Price for its Public ShareholdersNovember 13, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePULM, ALTS, MGNX, and EXOZ Company DescriptionsJanone NASDAQ:ALTS$5.51 +0.04 (+0.73%) Closing price 04:00 PM EasternExtended Trading$5.18 -0.33 (-6.06%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.Exozymes NASDAQ:EXOZ$13.53 +1.74 (+14.76%) As of 04:00 PM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.MacroGenics NASDAQ:MGNX$1.71 +0.19 (+12.50%) Closing price 04:00 PM EasternExtended Trading$1.67 -0.04 (-2.34%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Pulmatrix NASDAQ:PULM$6.47 +0.16 (+2.54%) Closing price 03:59 PM EasternExtended Trading$6.52 +0.04 (+0.70%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry? Amazon's Earnings Could Fuel a Rapid Breakout Tesla Earnings Miss, But Musk Refocuses and Bulls React Qualcomm’s Range Narrows Ahead of Earnings as Bulls Step In Meta Releases LLaMa 4: It Could Help Drive Big Growth Long Term Can IBM’s Q1 Earnings Spark a Breakout for the Stock? Could Palantir’s Latest Partnership Set a Base for a Move Higher? Dividend King Kimberly-Clark Is a Good Buy in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
